Nvidia insiders sold over $1 billion in stock amid market surge: Report
Nvidia insiders sold over $1 billion worth of company stock in the past year, with a notable uptick in recent trading activity as executives capitalize on surging investor interest in artificial intelligence, the Financial Times reported on Sunday.
More than $500 million of the share sales took place this month as the California-based chip designer's share price climbed to an all-time high, the report said.
Jensen Huang, Nvidia's chief executive, started selling shares this week for the first time since September, the SEC filing showed.
Nvidia's stock hit a record on Wednesday, and the chipmaker reclaimed the crown as the world's most valuable company after an analyst said the chipmaker was set to ride a "Golden Wave" of artificial intelligence.
Its latest gains reflect the U.S. stock market's return to the "AI trade" that fueled massive gains in chip stocks and related technology companies in recent years on optimism about the emerging technology.
Nvidia declined to comment on the FT report.
Reuters could not immediately confirm the report.
Nvidia's shares have rebounded over 60% from their closing low on April 4, when Wall Street was reeling from President Donald Trump's global tariff announcements. U.S. stocks, including Nvidia, have recovered on expectations the White House will reach trade deals to soften the tariffs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
39 minutes ago
- Time of India
Eggoz raises $20 million funding led by Gaja Capital
Egg brand Eggoz has raised $20 million (about Rs 167 crore) in fresh capital, with mid-market private-equity firm Gaja Capital anchoring the round. Key existing backers IvyCap Ventures, Rebright Partners, Avaana Capital, Merisis Opportunities Fund, Nabventures, Blue Dot Capital and Artek Chemicals, have also participated in the round, people familiar with the deal told company will be using the funds to penetrate deeper into the current markets in which it is already present, which includes major cities in North India, Bangalore, Hyderabad and Chennai in South India and Mumbai and Pune in the it will expand its business to East India in the coming months. 'The fund utilisation will be primarily to invest in growth which is to expand market footprint,' a source quoted above latest round brings the total fund raised by the Gurugram-based company to over $29 million. In 2022, Eggoz had raised $8.8 million in Series B funding, which was a mix of primary investment and secondary share sale, led by Mumbai-based IvyCap the financial year 2024-25, Eggoz reported a net revenue of Rs 130 crore which grew 76% year-on-year from Rs 74 crore reported in FY24. In the March quarter of FY25, the company achieved an Ebitda breakeven. This net revenue refers to the total revenue generated for the year after considering distribution margin, discounts given to customers, commissions to quick commerce platforms, was founded in 2017 by IIT Kharagpur alumni Abhishek Negi, Aditya Singh, and Uttam Kumar, the company has a presence in 11 cities. The brand sells premium eggs online , especially quick commerce, and offline through organised trade channels. In the last two years, the company has been growing fast on quick commerce platforms, according to the source quoted earlier."Eggoz has built mutual quality check guidelines with the quick commerce platforms to ensure the hygiene is maintained and the quality of the eggs are not compromised," the person cited above added, when asked about the ongoing hygiene issues in quick commerce dark stores in various this segment, other key players include Temasek-backed Licious, Coimbatore-based Suguna Chicken and Temasek and Venturi Partners-backed Country Delight's private label eggs. Bengaluru-based Licious, which also sells meat and seafood, is seeking to become profitable as it prepares to list in 2026. The firm is targeting a valuation of more than $2 billion in the listing.
Economic Times
42 minutes ago
- Economic Times
Eggoz raises $20 million funding led by Gaja Capital
iStock Egg brand Eggoz has raised $20 million (about Rs 167 crore) in fresh capital, with mid-market private-equity firm Gaja Capital anchoring the round. Key existing backers IvyCap Ventures, Rebright Partners, Avaana Capital, Merisis Opportunities Fund, Nabventures, Blue Dot Capital and Artek Chemicals, have also participated in the round, people familiar with the deal told company will be using the funds to penetrate deeper into the current markets in which it is already present, which includes major cities in North India, Bangalore, Hyderabad and Chennai in South India and Mumbai and Pune in the West. Further, it will expand its business to East India in the coming months. 'The fund utilisation will be primarily to invest in growth which is to expand market footprint,' a source quoted above said. The latest round brings the total fund raised by the Gurugram-based company to over $29 million. In 2022, Eggoz had raised $8.8 million in Series B funding, which was a mix of primary investment and secondary share sale, led by Mumbai-based IvyCap the financial year 2024-25, Eggoz reported a net revenue of Rs 130 crore which grew 76% year-on-year from Rs 74 crore reported in FY24. In the March quarter of FY25, the company achieved an Ebitda breakeven. This net revenue refers to the total revenue generated for the year after considering distribution margin, discounts given to customers, commissions to quick commerce platforms, etc. Eggoz was founded in 2017 by IIT Kharagpur alumni Abhishek Negi, Aditya Singh, and Uttam Kumar, the company has a presence in 11 cities. The brand sells premium eggs online, especially quick commerce, and offline through organised trade channels. In the last two years, the company has been growing fast on quick commerce platforms, according to the source quoted earlier. "Eggoz has built mutual quality check guidelines with the quick commerce platforms to ensure the hygiene is maintained and the quality of the eggs are not compromised," the person cited above added, when asked about the ongoing hygiene issues in quick commerce dark stores in various this segment, other key players include Temasek-backed Licious, Coimbatore-based Suguna Chicken and Temasek and Venturi Partners-backed Country Delight's private label eggs. Bengaluru-based Licious, which also sells meat and seafood, is seeking to become profitable as it prepares to list in 2026. The firm is targeting a valuation of more than $2 billion in the listing. Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Someone has to cut the cheque for Zepto to grow. Who's that? Drones have become a winning strategy in war; can they be in investing? Punit Goenka reloads Zee with Bullet and OTT focus. Can he beat mighty rivals? Profits plenty, prices attractive, still PSU stocks languish. Why? Stock Radar: Indus Tower stock breaks out from Symmetrical Triangle pattern; could hit fresh 52-week high – check target & stop loss Mid-cap pharma space: Risk & opportunity are two sides of the same coin. 7 pharma stocks with upside potential of up to 41% History on their side: As bulls return, 50 non-Nifty stocks with a higher probability of trading income & creating wealth Beyond the one-number mirage: 7 stocks from different sectors with an upside potential of up to 24%
Time of India
an hour ago
- Time of India
Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuation
Torrent Pharma will acquire a controlling stake in JB Chemicals from KKR. The deal values JB Chemicals at Rs 25,689 crore. This merger will elevate Torrent to fifth position in the Indian pharmaceutical market. KKR is expected to gain a fivefold return on its 2020 investment. The combined entity aims for significant revenue and profitability growth. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of Rs 25,689 crore ($3 billion). The deal, which will see a merger of the two entities, is among the biggest in the Indian pharmaceutical sector and brings to an end year-long negotiations. They had come close to a deal last year but couldn't agree on valuation at the the acquisition of JB Chemicals, Torrent will move up to fifth rank by market share in the $26 billion Indian pharmaceutical market ahead of Alkem and Intas Pharma. ET had on June 29 been the first to report on the merger deal was announced following a marathon meeting of Torrent Pharma's board of directors on against the stock's Friday close of Rs 1,792. Torrent will also acquire up to 2.8% equity from certain employees of JB Chemicals at the Rs 1,600 apiece. The second part of the deal will follow amerger between Torrent and JB Chemicals through a scheme of arrangement. As per the approval by the two boards, upon the merger, every shareholder holding 100 shares in JB Chemicals will get 51 shares of Torrent. KKR had been the first to seek a restart of negotiations, according to the people cited above. Even at the discounted price, it will end with a fivefold return on what it paid to acquire JB Chemicals in Pharma posted FY25 revenue of Rs 11,500 crore, of which the Indian market accounted for Rs 6,393 crore. JB Chemicals recorded total FY25 sales of Rs 3,918 crore, of which the Indian market accounted for Rs 2,269 crore, growing at 20% over the previous the last decade, Torrent has grown inorganically with a string of deals that included skincare drugs maker Curatio in 2022 and more recently a range of anti-diabetes drugs from Boehringer Ingelheim. Apress statement from Torrent Pharma said the transaction marks a significant step in its ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO (contract development and manufacturing) capabilities. The deal is a strong fit for Torrent and complements its India presence, helping it move into the promising field of contract manufacturing besides allowing for market synergy, an analyst said. 'Torrent has a proven record of making deals work successfully,' the person company will get access to leading brands in the chronic segment and entry into untapped therapeutic areas such as ophthalmology. Torrent said it will derive operational synergies across multiple business functions. 'We are pleased to have on board the JB Chemicals heritage and build on the platform for the future,' said Torrent Pharma executive chairman Samir Mehta. 'Torrent's deep India presence and JB Chemicals' fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability.'For KKR, this follows strong investment activity in India, where the buyout group has deployed more than $2 billion in private equity investments in the past year alone, in addition to a recent $600 million financing of Manipal Group. This also builds on KKR's strong healthcare track record, including a fivefold return in Max Healthcare in 2022 that had also marked the largest block deal by a private equity firm in India, and recent investments in healthcare, including Healthcare Global Enterprises, BMH (Baby Memorial Hospital), Healthium and Chemicals said it had built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. 'As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets,' said Nikhil Chopra, chief executive officer and whole time director of JB Chemicals.
